天津医药 ›› 2026, Vol. 54 ›› Issue (11): 1177-1182.doi: 10.11958/20260799

• 临床研究 • 上一篇    下一篇

血清MCP-1、TRAIL、CRP/ALb水平与新生儿坏死性小肠结肠炎患儿预后的关系

高兴(), 李辰, 葛爽爽, 苗耐英△()   

  1. 河北中石油中心医院儿科 (邮编 065000)
  • 收稿日期:2026-04-01 修回日期:2026-06-30 出版日期:2026-11-15 发布日期:2026-11-10
  • 通讯作者: 苗耐英 E-mail:245789762@qq.com;44242278@qq.com
  • 作者简介:高兴(1991),女,主治医师,主要从事新生儿科方面研究。E-mail:245789762@qq.com
  • 基金资助:
    廊坊市科技支撑计划项目(2023013037)

The relationship between serum MCP-1, TRAIL, CRP/ALb levels and the prognosis of neonates with necrotizing enterocolitis

GAO Xing(), LI Chen, GE Shuangshuang, MIAO Naiying△()   

  1. Department of Pediatrics, Hebei PetroChina Central Hospital, Langfang 065000, China
  • Received:2026-04-01 Revised:2026-06-30 Published:2026-11-15 Online:2026-11-10
  • Contact: MIAO Naiying E-mail:245789762@qq.com;44242278@qq.com

摘要:

目的 探究血清单核细胞趋化蛋白-1(MCP-1)、肿瘤坏死因子相关凋亡诱导配体(TRAIL)、C反应蛋白/白蛋白比值(CRP/ALb)水平与新生儿坏死性小肠结肠炎(NEC)患儿预后的关系。方法 纳入2022年8月—2024年12月于该院确诊的127例NEC新生儿作为NEC组,并根据预后情况分为预后良好组(89例)和预后不良组(38例);选取同期于该院出生的127例健康新生儿作为对照组。检测血清MCP-1、TRAIL、CRP及ALb水平,计算CRP/ALb。采用多因素Logistic回归分析筛选影响NEC预后的因素;采用受试者工作特征(ROC)曲线评估血清MCP-1、TRAIL、CRP/ALb单独及联合检测对NEC预后的预测价值,并以决策曲线分析(DCA)评估预测模型的临床价值。结果 与对照组相比,NEC组血清MCP-1、TRAIL、CRP/ALb水平升高(P<0.05)。与预后良好组相比,预后不良组患儿血清中MCP-1、TRAIL、CRP/ALb水平及Bell分期为Ⅱ—Ⅲ期比例升高,且上述指标均为NEC患儿预后的独立影响因素(P<0.05)。血清MCP-1、TRAIL、CRP/ALb单独预测NEC患儿预后的曲线下面积(AUC)分别为0.874(95%CI:0.804~0.926)、0.865(95%CI:0.793~0.919)、0.897(95%CI:0.831~0.944),三者联合预测的AUC为0.963(95%CI:0.914~0.989),显著优于单一指标(P<0.05);DCA显示,在0.04~0.96阈值范围内联合预测的临床净获益更高。外部验证结果显示,三者单独预测的AUC为0.798(95%CI:0.688~0.883)、0.841(95%CI:0.737~0.916)、0.878(95%CI:0.781~0.943),联合预测AUC为0.957(95%CI:0.881~0.990),显著优于单独检测(P<0.05);在0.06~0.96的阈值概率范围内,联合预测的临床净获益高于单独检测。结论 血清MCP-1、TRAIL、CRP/ALb联合检测对NEC患儿预后不良具有较高的预测效能,该预测模型具有良好的临床实用性。

关键词: 小肠结肠炎,坏死性, 婴儿,新生, 趋化因子CCL2, 肿瘤坏死因子相关凋亡诱导配体, C反应蛋白/白蛋白比值

Abstract:

Objective To explore the relationship between the levels of serum monocyte chemoattractant protein-1 (MCP-1), tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), C-reactive protein/albumin ratio (CRP/ALb) and the prognosis of neonatal necrotizing enterocolitis (NEC) in infants. Methods A total of 127 newborns diagnosed with NEC in our hospital from August 2022 to December 2024 were included as the study subjects, denoted as the NEC group. These infants were further divided into the good prognosis group (n=89) and the poor prognosis group (n=38) based on the children's prognosis. Meanwhile, 127 healthy newborns born in our hospital during the same period were selected as the control (NC) group. Serum levels of MCP-1, TRAIL, CRP and ALb were measured, and the CRP/ALb ratio was calculated. Multivariate Logistic regression analysis was used to screen factors affecting NEC prognosis. Receiver operating characteristic curves (ROC) were constructed to evaluate the predictive values of serum MCP-1, TRAIL, CRP/ALb levels individually and in combination for NEC prognosis. Decision curve analysis (DCA) was used to assess the clinical value of the above predictive models. Results Compared with the NC group, levels of serum MCP-1, TRAIL and CRP/ALb were significantly elevated in the NEC group (P < 0.05). Compared with the good prognosis group, levels of serum MCP-1, TRAIL and CRP/ALb were significantly increased in the poor prognosis group, with a significantly higher proportion of patients in Bell stages Ⅱ-Ⅲ. These indicators were independent influencing factors for the prognosis of NEC patients (P < 0.05). The AUCs for predicting the prognosis of NEC patients using serum MCP-1, TRAIL and CRP/ALb alone were 0.874 (95%CI: 0.804-0.926), 0.865 (95%CI: 0.793-0.919) and 0.897 (95%CI: 0.831-0.944), respectively. The area under the curve (AUC) for combined prediction was 0.963 (95%CI: 0.914-0.989), which was significantly superior to that of individual indicators. Within the threshold range of 0.04-0.96, combined prediction yielded higher net clinical benefit. External validation showed that the AUCs for individual prediction using these three markers were 0.798 (95%CI: 0.688-0.883), 0.841 (95%CI: 0.737-0.916) and 0.878 (95%CI: 0.781-0.943), respectively. The AUC for combined prediction was 0.957 (95%CI: 0.881-0.990), which was significantly better than that of individual indicator. Within the threshold range of 0.06-0.96, combined prediction yielded higher net clinical benefit than individual prediction. Conclusion The combined detection of serum MCP-1, TRAIL and CRP/ALb has a high predictive efficacy for poor prognosis in NEC, and this predictive model has good clinical practicality.

Key words: enterocolitis, necrotizing, infant, newborn, chemokine CCL2, tumor necrosis factor-related apoptosis-inducing ligand, C-reactive protein to albumin ratio

中图分类号: